{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:54:12Z","timestamp":1773813252373,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["epilepsybehavior.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.yebeh.2016.08.005","type":"journal-article","created":{"date-parts":[[2016,10,15]],"date-time":"2016-10-15T18:45:20Z","timestamp":1476557120000},"page":"216-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"PA","title":["Behavioral effects and somnolence due to levetiracetam versus oxcarbazepine \u2014 a retrospective comparison study of North Indian patients with refractory epilepsy"],"prefix":"10.1016","volume":"64","author":[{"given":"Garima","family":"Shukla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anupama","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivani","family":"Poornima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2016.08.005_bb0005","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1059-1311(02)00251-0","article-title":"Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy","volume":"12","author":"Ben-Menachem","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2016.08.005_bb0010","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1212\/01.wnl.0000268699.34614.d3","article-title":"Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy","volume":"69","author":"Berkovic","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2016.08.005_bb0015","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/seiz.2000.0380","article-title":"A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000mg daily and 4000mg daily, without titration in patients with refractory epilepsy","volume":"9","author":"Betts","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2016.08.005_bb0020","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/bcp.12083","article-title":"Comparative efficacy and tolerability of anti-epileptic drugs for refractory focal epilepsy: systematic review and network meta-analysis reveals the need for long term comparator trials","volume":"76","author":"Bodalia","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2016.08.005_bb0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.seizure.2015.07.004","article-title":"The adverse event profile of levetiracetam: a meta-analysis on children and adults","volume":"31","author":"Verrotti","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2016.08.005_bb0030","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.seizure.2014.06.004","article-title":"Behavioral side-effects of levetiracetam in children with epilepsy: a systematic review","volume":"23","author":"Halma","year":"2014","journal-title":"Seizure"},{"issue":"9566","key":"10.1016\/j.yebeh.2016.08.005_bb0035","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.yebeh.2016.08.005_bb0040","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1212\/WNL.0b013e31826d5ec0","article-title":"Efficacy of antiepileptic drugs in adults predicts efficacy in children \u2014 a systematic review","volume":"79","author":"Pellock","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2016.08.005_bb0045","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1474-4422(12)70018-2","article-title":"Prognostic factors for time to treatment failure and time to 12months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial","volume":"4","author":"Bonnett","year":"2012","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.yebeh.2016.08.005_bb0050","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1006\/ebeh.2000.0126","article-title":"Oxcarbazepine for treatment of partial epilepsy: a review and recommendations for clinical use","volume":"1","author":"Schmidt","year":"2000","journal-title":"Epilepsy Behav"},{"issue":"1","key":"10.1016\/j.yebeh.2016.08.005_bb0055","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1111\/j.1528-1167.2011.03318.x","article-title":"Efficacy, tolerability, and pharmacokinetics of oxcarbazepine on oral loading in patients with epilepsy","volume":"53","author":"Kim","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.08.005_bb0060","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006453.pub2","article-title":"Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures","volume":"4","author":"Koch","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.yebeh.2016.08.005_bb0065","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1345\/aph.1E136","article-title":"Clinical, cognitive, and neurophysiologic correlates of short-term treatment with carbamazepine, oxcarbazepine, and levetiracetam in healthy volunteers","volume":"38","author":"Mecarelli","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.yebeh.2016.08.005_bb0070","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.seizure.2007.12.003","article-title":"Central nervous system adverse effects of new antiepileptic drugs \u2014 a meta-analysis of placebo-controlled studies","volume":"17","author":"Zaccara","year":"2008","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2016.08.005_bb0075","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.seizure.2005.12.008","article-title":"Oxcarbazepine reduces seizure frequency in a high proportion of patients with both newly diagnosed and refractory partial seizures in clinical practice","volume":"15","author":"Pauletto","year":"2006","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.yebeh.2016.08.005_bb0080","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00213-010-1814-y","article-title":"Effects of oxcarbazepine and carbamazepine on driving ability: a double-blind, randomized crossover trial with healthy volunteers","volume":"210","author":"Kaussner","year":"2010","journal-title":"Psychopharmacology (Berl)"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505016303493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505016303493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T12:22:51Z","timestamp":1536322971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505016303493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":16,"alternative-id":["S1525505016303493"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2016.08.005","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Behavioral effects and somnolence due to levetiracetam versus oxcarbazepine \u2014 a retrospective comparison study of North Indian patients with refractory epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2016.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}